Recent findings from the randomized phase III J-SONIC trial revealed significantly prolonged overall survival with the triple combination of nintedanib, carboplatin, and nanoparticle albumin-bound paclitaxel versus the doublet regimen of carboplatin and nab-paclitaxel in advanced non-squamous non-small-cell lung cancer (NSCLC) patients with concurrent IPF. The gene discussed is ALB; the disease is idiopathic pulmonary fibrosis.